Form 4: Neurogene CFO Sells Shares for Tax Obligations

Neurogene Inc.'s President and CFO, Christine Mikail Cvijic, sold common stock on March 13, 2026, to cover tax withholding responsibilities related to a vested Restricted Stock Unit award.

Summary

• Christine Mikail Cvijic, President and CFO of Neurogene Inc. (NGNE), reported the sale of 4,045 shares of common stock on March 13, 2026.
• The sales were executed in multiple transactions at weighted average prices of $20.4224, $21.2451, and $22.0195.
• These sales were mandatory and solely to cover tax withholding obligations arising from the partial vesting of a Restricted Stock Unit (RSU) award on March 12, 2025, with no election made by the reporting person.
• Following these transactions, Christine Mikail Cvijic beneficially owns 105,798 shares of Neurogene Inc. common stock.
• The remaining beneficial ownership includes 10,635 restricted stock units granted on March 13, 2024, vesting on March 13, 2027; 20,300 restricted stock units granted on March 26, 2025, vesting annually in equal installments on March 26, 2026, 2027, and 2028; and 22,000 restricted stock units granted on February 20, 2026, vesting annually in equal installments on February 20, 2027, 2028, and 2029.
• Additionally, 19,200 shares are held jointly by the reporting person and her spouse, David Cvijic.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as largely neutral. The sale of shares is a mandatory event to cover tax obligations from RSU vesting, which is a routine part of executive compensation and not a discretionary divestment.

Positives

• The vesting of Restricted Stock Units (RSUs) indicates that the executive is receiving compensation, which is a standard component of executive remuneration.
• The company's stock price at the time of sale (ranging from $19.92 to $22.075) reflects a certain level of market valuation, enabling the executive to cover tax liabilities.

Negatives

• The sale of shares by an insider, even for tax purposes, can sometimes be misinterpreted by the market as a lack of confidence, although the filing explicitly states it was a mandatory tax-related sale.

Future Outlook

This Form 4 filing does not contain forward-looking statements or guidance regarding the company's future financial performance or strategic outlook.

Industry Context

StockSavvy.ai notes that Form 4 filings detailing executive stock transactions, particularly those related to RSU vesting and mandatory tax withholding sales, are routine occurrences in publicly traded companies. These transactions are a common aspect of executive compensation and do not typically indicate a change in company fundamentals or strategic direction.

Stakeholder Impact

• Shareholders: The transaction is a routine insider sale for tax purposes and is unlikely to have a significant direct impact on shareholder value or perception, given its mandatory nature and relatively small volume compared to total outstanding shares.
• Employees: No direct impact on employees is indicated by this filing.

Next Steps

• Future vesting of restricted stock units on March 26, 2026, March 13, 2027, March 26, 2027, February 20, 2027, March 26, 2028, February 20, 2028, and February 20, 2029, as detailed in the filing.

Key Dates

Keywords

Neurogene Inc., NGNE, Form 4, insider transaction, stock sale, Restricted Stock Unit, RSU, tax withholding, executive compensation, Christine Mikail Cvijic